Stock comparison
Organon &
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
OGN
Organon &
Market cap
$3.53B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | OGN | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 57C | 71B | UTHR |
| Benjamin Graham | 78B | 76B | OGN |
| Philip Fisher | 38D | 76B | UTHR |
| Peter Lynch | 27F | 62C | UTHR |
| Joel Greenblatt | 21F | 46D | UTHR |
| Charlie Munger | 48D | 64C | UTHR |
| Terry Smith | 46D | 64C | UTHR |
Side-by-side metrics
| Metric | OGN | UTHR |
|---|---|---|
| Market cap | $3.53B | $24.13B |
| P/E (TTM) | 14.2x | 19.2x |
| EV/EBIT | 8.5x | 15.2x |
| ROIC (TTM) | 5.16% | 18.81% |
| Gross margin | 53.11% | 86.58% |
| Net margin | 3.99% | 40.61% |
| Revenue CAGR 5y | -0.35% | 17.22% |
| EPS CAGR 5y | -39.38% | 29.84% |
| Debt / Equity | 9.5x | - |
| Dividend yield | 0.6% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
OGN leads on
- Dividend yield0.6%vs 0.0%+100%
- EV/EBIT8.5xvs 15.2x+44%
- P/E (TTM)14.2xvs 19.2x+26%
UTHR leads on
- EPS CAGR 5y29.84%vs -39.38%+176%
- Revenue CAGR 5y17.22%vs -0.35%+102%
- Debt / Equity-vs 9.5x+100%
- Net margin40.61%vs 3.99%+90%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.